Top Ten Transaction Counties: Foreign Pharmaceutical Enterprises Frequency | 'Slimming'

Pharmaceutical Network Nov. 21 hearing With the expiry of the patent protection of the original pharmaceutical drug companies in China and the impact of local Chinese R & D enterprises, a large number of low-priced generic drugs are listed on the market. The sales of foreign-funded original drug companies in China have slowed down, Even varying degrees of shrinking.

Foreign companies 'downsizing' campaign has begun.

In order to save costs, focus on the core areas and improve the efficiency of resource utilization, foreign enterprises focus their efforts on innovative medicines that are not easy to be imitated by stripping products and transferring sales rights, etc. On the other hand, in order to quickly replenish product lines and strengthen their advantages Areas, expand cash flow, enhance the competitiveness of enterprises, have strived to 'accept Panxian.'

This article combines the online disclosure of reports since 2016 to summarize the information on the mature products imported by foreign pharmaceutical enterprises by domestic pharmaceutical companies:

During the cooperation period, Bayer will bring its total sales of its five brands of "Baica Black" to Shanghai Pharmaceutical Holdings Co., Ltd. for its commercial operation in the Chinese market. Shanghai Pharmaceutical Holdings will provide Bayer with a nation-wide supply chain including strategy formulation, marketing and promotion, Management and related work integration services.The reason for their cooperation, mainly Bayer this large foreign-funded enterprises for terminal channel control ability is often not as flexible as local enterprises, and Bayer also fancy medicine on the grassroots level and chain pharmacy market high Share.

The other hand, the drug, the company set up for the cooperation of the national contract sales headquarters, the five varieties will be carried out by sales representatives hospital Academic promotion, commercial channel expansion and OTC chain terminal coverage, to meet the drug to speed up the transformation of modern pharmaceutical supply chain services and corporate strategy.

AstraZeneca's cooperation with them will help them launch their strategic plan in the world's second-largest market in China, in cooperation with local enterprises drug Of the interests of the largest and Kangzhe through cooperation, can give full play to the advantages of front-line sales team, the layout of channels to effectively improve product coverage and sales.

According to Kangzhe Pharmaceutical's semi-annual report 2017, benefiting from academic promotion, while strengthening the core market and strengthening the market coverage and infiltration, Bo Yi Ding achieved an income of 643 million yuan, an increase of 134.2% over the same period of last year. This shows the advantages after the cooperation Is gradually shown.

Avita is concerned that every year 3.4 million Chinese patients are hospitalized for burns and 1.4 million people suffer from vitiligo. This is the main group that Avita's skin care products are applicable to. After Avita entered the Chinese market in 2012, A better market layout, and this cooperation will be able to better meet the Chinese market demand for Avita renewable medical products.

Set up in 1995, Sinopharm Medical (Shanghai) Co., Ltd. was established in 1995. Its predecessor is Shanghai Mei Tai Medical Equipment Co., Ltd., which is a comprehensive solution focused on hospital modern logistics solutions, operating room and ICU solutions, infection control, Pharmacy automation solutions and surgical consumables.We have established long-term and good cooperative relations with more than 3000 hospitals and medical institutions across the country and have more than 280 staff members. This cooperation will enrich the company's sales product line and further bring sales Gain.

In May 2016, Teleling Pharma announced that it has acquired the Novartis Pharmaceutical Orthopedic brand 'Gentle Interest', which includes the relevant intellectual property rights, licenses and other assets, with a transaction amount of USD 145 million. Tailin Pharmaceutical will receive the license from China (including RTHK) , Korea, Southeast Asia, India and other major Asia-Pacific regions as well as other parts of the world such as Switzerland, Australia, Russia, Brazil and South Africa, etc. For Tailin Pharmaceutical, the acquisition of MclI brand will enrich its therapeutic line of products , Strategically into the field of orthopedics.

Tyler 2017 semi-annual report shows that the first half of the infiltration covered 155 million yuan, of which 115 million yuan for brand licensing fees, self-sales of 39.7 million yuan.

France LFB and Yaobao jointly introduce VIALEBEX, the world's leading human albumin product into China, and Yaobao Pharmaceutical has become the exclusive Chinese market for this product proxy.

In recent years, Ya Bao Pharmaceutical to take 'go out and bring in' approach to strengthen international cooperation from developed countries to introduce advanced management and technology and high-end talent and products, the introduction of the VIALEBEX Ya Bao Pharmaceutical many international In addition, Yabao Pharmaceutical Co., Ltd. and Eli Lilly of the United States to develop new drugs for the treatment of diabetes; and the National Institute of Science and Technology cooperation in the development of new drugs for the treatment of Parkinson's disease; and the University of South Australia to establish a cooperation Laboratories to develop new anti-tumor drugs; and Rosen Institute of Health in Canada to develop new drugs for the treatment of sepsis; and two academicians in Canada to develop new drugs for the treatment of stroke; and the United States sciecure / salus pharmaceutical companies to develop four controlled release Products; And Hesse R & D company in the United States to establish a laboratory in Beijing, joint research innovative drugs and so on.

In July 2016, GlaxoSmithKline China announced an agreement with Cadesis Pharmaceutical Holding Group to approve the transfer of its equity interests in Nanjing Mercury Pharmaceuticals and three types of urinary products including, Sustained release tablets and that properly, by Kaida Sida took over the production and marketing operations.

It is understood that Nanjing Mei Rui Pharmaceutical Co., Ltd. is GSK in 2010 cost 70 million acquisition of a pharmaceutical in China enterprise Mainly engaged in the research and manufacture of specialized products for the diagnosis and treatment of urological diseases, GSK will focus its operations in China on such key areas as respiration, hepatitis, vaccines, AIDS, central nervous system and thrombosis We will continue to focus our efforts on this area to better provide medical assistance to Chinese patients.

Kaide Sida Pharmaceutical Holdings Group was founded in 2000, the company's sales volume of 2.53 billion yuan, the average annual growth rate of 23.8% in the field of antibiotics, cardiovascular and cerebrovascular markets, liver disease, cancer products in the industry-leading sales The success of this acquisition will help the Group improve the pharmaceutical industry plate layout, significantly enhance the Group's overall production quality management technology to further enrich the Group's product line. Cade Star will take full advantage of the Swiss production capacity, technological advantages and staff skills , Continue to develop, provide patients with quality medicines, provide long-term development and growth opportunities for employees.

The core of Greenery's global strategy is to keep pace with both the Chinese and international markets through collaborative M & A, R & D, brand marketing and international quality standards. The acquisition is exactly where Acino is the largest independent transdermal system manufacturer in Europe First, while the global market for transdermal drug delivery is large and has strong potential for growth, the global population aging trend will significantly increase the demand for chronic disease management and the transdermal drug delivery business is undoubtedly a huge market. Pharmaceutical said the next step will be fully integrated with its own experience and advantages in the Chinese market, to open up new market opportunities for transdermal drug delivery and development space.

In October 2016, Sansheng Pharmaceutical announced that its wholly owned subsidiary, Hong Kong Sansheng signed an exclusive license agreement with AstraZeneca to acquire the latter four products in the field of diabetes with a total allowable price of 100 million U.S. dollars. The exclusive license period 20 years. The four products are: Byetta, Bydureon, Bydureondualchamberpen, Bydureonautoinjector. The cooperation, the Sansheng Group product line in the field of diabetes have a strong expansion and market penetration, will also integrate AstraZeneca's sales team to establish a A team of professionals in the field of Diabetes, a better layout diabetes.

In November 2016, the pharmaceutical giant Eli Lilly China announced that it has reached an exclusive agreement with Yiteng Pharma, a Chinese pharmaceutical company, to promote and promote the two products of its anti-health and health care products The distribution right was officially granted to Yi Teng Pharmaceutical on January 1, 2017.

This is for the Yi Teng in the field of anti-infective content strength has a certain enhancement.In this, Yi Teng infection line is only one anti-infectives Xili Xin. The Eli Lilly and the main drug: Chi Kelao and steady Letter, is Lilly anti-infective product line veteran products, with high recognition of clinicians.

In the same month, Eterna announced that it has signed an exclusive commercial license agreement with Zolpimist ™ (Zolpidem Tartrate Oral Spray), a new drug used to treat insomnia. The new drug will be The first imported oral zolpidem tartrate-based oral spray available in the Chinese market, through which it will expand its portfolio of products with a well-aligned business strategy.

Domestic access Pan, the author focused on the more active pharmaceutical Hymeni in Tibet. Public information shows that Hymenone Pharmaceutical Co., Ltd. started in 2002, is a collection research and development, production, sales, professional promotion in one Since the founding of Hymenone Pharmaceutical Co., Ltd., in order to seize the market, in 2013-2017, we have been cooperating with a number of enterprises to continuously enrich our product line and ensure our market advantage in the sales field.

2013 - 2017 Hymenone Pharmaceuticals introduced product statistics